Chemoprevention of Breast Cancer

Release Date: July 2002

Summary of Recommendations / Supporting Documents

Summary of Recommendations

• The U.S. Preventive Services Task Force (USPSTF) recommends against routine use of tamoxifen or raloxifene for the primary prevention of breast cancer in women at low or average risk for breast cancer. (Go to Clinical Considerations for a discussion of risk.)
  Grade: D Recommendation.
• The USPSTF recommends that clinicians discuss chemoprevention with women at high risk for breast cancer and at low risk for adverse effects of chemoprevention. Clinicians should inform patients of the potential benefits and harms of chemoprevention.
  Grade: B Recommendation.

Top of Page

Supporting Documents

Chemoprevention of Breast Cancer, July 2002
Recommendations and Rationale (PDF file, 89 KB; PDF Help)
Summary of the Evidence (PDF File, 224 KB; PDF Help)
Systematic Evidence Review
What's New (PDF File, 75 KB; PDF Help)

Top of Page

Current as of July 2002

Internet Citation:

Chemoprevention of Breast Cancer, Topic Page. July 2002. U.S. Preventive Services Task Force. Agency for Healthcare Research and Quality, Rockville, MD. http://www.ahrq.gov/clinic/uspstf/uspsbrpv.htm